A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma

Teis Esben Søndergaard, PT Pedersen, Thomas Levin Andersen, K Søe, T Lund, B Ostergaard, P Garnero, Jean-Marie Delaissé, T Plesner

Research output: Contribution to journal › Journal article › Research › peer-review

Fingerprint

Dive into the research topics of 'A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science